Tagrisso Reduced Lung Cancer Death Risk
Clinical trial results presented in 2026 showed significant long-term survival improvements for treated patients.
Updated on Sept. 21, 2026 in Cancer
Live Poll
Do you trust that recent medical trial results accurately reflect long-term benefits for cancer patients?
Tagrisso demonstrated a 47% reduction in the risk of death for patients with Stage II to IIIA EGFR-mutated non-small cell lung cancer. The findings, presented in 2026, highlighted long-term efficacy after complete tumor resection.
Why it matters
These results provide critical evidence for the use of adjuvant therapy to extend survival in patients with specific lung cancer mutations. The data underscores the importance of completing the full three-year treatment course to prevent disease recurrence.
In the broader trial population, Tagrisso reduced the risk of death by 48% compared to placebo. Eight-year survival was estimated at 79% for the treatment group versus 64% for the placebo group, with a hazard ratio of 0.53 for Stage II to IIIA disease.
The players
International Association for the Study of Lung Cancer
This global organization facilitates research and communication among professionals dedicated to the study and treatment of lung cancer.
The details
The trial evaluated Tagrisso in patients following complete surgical tumor resection with curative intent. Researchers determined that discontinuing the medication before the full three-year treatment course doubled the risk of disease recurrence or death.
Timeline
2026: Results were presented at the World Conference on Lung Cancer in Seoul.
8 years post-treatment: Estimated patient survival rates were recorded.
The Big Picture
This presentation follows the scientific standard set by the World Conference on Lung Cancer. The study updates the long-term survival benchmarks previously established by clinical data presented at this conference.
Patients with EGFR-mutated non-small cell lung cancer should discuss the necessity of completing the full three-year treatment regimen with their oncologists. Adherence to the prescribed course is vital, as early discontinuation has been shown to significantly increase the risk of recurrence.
The takeaway
Long-term data confirms that sustained adjuvant treatment can substantially increase survival rates for specific lung cancer patient groups. Following the full duration of a prescribed course is essential for maximizing therapeutic outcomes.
Further reading
Learn more about the latest clinical advancements in the Cancer section.
Live Poll
Do you trust that recent medical trial results accurately reflect long-term benefits for cancer patients?
